In May, Novavax acquired the Czech vaccine manufacturing facility Praha Vaccines, which is actually located in Bohumil, about 20 kilometers east of Prague, for about 3.5 billion crowns. They bought the Czech plant with the expressed intent to use it to manufacture NVX-CoV2373.